Kaposi's sarcoma in Zimbabwe. II. Peripheral lymphocytes, immunoglobulin G levels and HIV antibody positivity. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Kaposi's sarcoma in Zimbabwe. II. Peripheral lymphocytes, immunoglobulin G levels and HIV antibody positivity.

J Clin Lab Immunol. 1988 Sep;27(1):25-8. Unique Identifier : AIDSLINE MED/89279885
Wilcock G; Grace S; De Villiers D; Borok MZ; Emmanual J; Downing R; Department of Physiology, University of Zimbabwe, Harare.

Abstract: Patients with Kaposi's Sarcoma (KS) were grouped according to their clinical symptoms into indolent, locally aggressive, endemic generalised aggressive and epidemic generalised aggressive disease. Only the patients in the epidemic generalised aggressive disease group had serum antibodies to HIV. Complete peripheral blood counts, including lymphocyte subsets, and serum IgG assays were performed on all patients before treatment was initiated. In all the aggressive disease groups there was evidence of immune deficiency in that T helper/inducer (T4) cells were reduced leading to reduced T4,T8 (suppresser/cytotoxic) ratio. All patient groups had increased levels of serum IgG. Although immune deficiency and aggressive KS can be explained in the HIV infected patients no underlying cause has been found in the HIV negative patients with aggressive KS.
Keywords: Human HIV Antibodies/ANALYSIS HIV Seropositivity/EPIDEMIOLOGY/*IMMUNOLOGY IgG/*ANALYSIS Leukocyte Count Lymphocytes/*IMMUNOLOGY Sarcoma, Kaposi's/EPIDEMIOLOGY/*IMMUNOLOGY Zimbabwe JOURNAL ARTICLE

KWDhumanhivantibodies/analysishivseropositivity/epidemiology/KWDimmunologyigg/KWDanalysisleukocytecountlymphocytes/KWDimmunologysarcoma,kaposi's/epidemiology/KWDimmunologyzimbabwejournalarticle
890930
M8990777

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .